One of these challenges is improving efficiency in gene delivery.
Electroporation is currently one of the most efficient methods for gene delivery and is commonly used for virus-free gene therapy. However, following electroporation, viability and expansion capacity of cells are markedly reduced. GenomeFrontier’s Quantum Nufect™ overcomes these challenges of inefficient gene delivery and low cell viability following electroporation.
Quantum Nufect™ is a highly efficient and cost-effective universal electroporation buffer system. In conjunction with an electroporator (e.g. Lonza nucleofector™), it can be used to efficiently introduce DNAs, RNAs, or proteins into multiple cell types with minimal reduction in cell viability.
We demonstrated that Quantum Nufect™ facilitates highly efficient vector delivery into several hard-to-transfect cell types, including human primary T cells (see Figure 1). We further demonstrated that during CAR-T cell production, Quantum Nufect™ not only preserves the viability of engineered T cells but also enhances cell expansion following electroporation. These evidence suggest potential benefits for using Quantum Nufect™ as a buffer system to manufacture clinical-scaled virus-free gene-modified cells.
